<DOC>
	<DOCNO>NCT02496767</DOCNO>
	<brief_summary>This study assess effect tirasemtiv versus placebo respiratory function patient ALS .</brief_summary>
	<brief_title>Ventilatory Investigation Tirasemtiv Assessment Longitudinal Indices After Treatment Year</brief_title>
	<detailed_description>CY 4031 multi-national , double-blind , randomize , placebo-controlled , stratified , parallel group study patient ALS selective fast skeletal muscle troponin activator , tirasemtiv . The study include three phase ; open-label phase ( 2 week ) , double-blind , placebo-controlled phase ( 48 week ) , double-blind , placebo-controlled tirasemtiv withdrawal phase ( 4 week ) . Patients complete two week treatment open-label tirasemtiv ( 125 mg twice daily ) randomize 3:2:2:2 placebo three different dose level tirasemtiv . Approximately 600 patient enrol onto open-label treatment . Patients enter study riluzole 50 mg twice daily continue riluzole reduce dose 50 mg daily .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>A diagnosis familial sporadic ALS ( define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion ) ≤ 24 month prior screen Upright SVC ≥ 70 % predicted age , height sex Able swallow tablet without crush , opinion Investigator , expect continue able trial A caregiver one need Clinical laboratory finding within normal range , outside normal range , deem clinically significant Investigator Male patient must agree duration study 10 week end study use condom sexual intercourse female partner childbearing potential ( i.e. , follow menarche postmenopausal anatomically physiologically incapable become pregnant ) female partner use additional effective mean contraception ( e.g. , diaphragm plus spermicide , oral contraceptive ) male patient must agree abstain sexual intercourse 10 week end study , unless male patient vasectomy confirm sperm count zero Female patient must postmenopausal ( ≥ 1 year ) sterilize , , childbearing potential , breastfeeding , negative pregnancy test , intention become pregnant course study , use effective contraceptive drug device require male partner use condom duration study 10 week end study Patients must either stable dose riluzole 50 mg twice daily least 30 day prior screen take riluzole least 30 day prior screen willing begin riluzole use complete study drug dose At time screening , use noninvasive positive pressure ventilation ( NIPPV , e.g . continuous positive airway pressure [ CPAP ] bilevel positive airway pressure [ BiPAP ] ) portion day , mechanical ventilation via tracheostomy , form oxygen supplementation Patients diaphragm pace system ( DPS ) study entry anticipate DPS placement course study BMI 20.0 kg/m2 lower Unwilling unable discontinue tizanidine theophyllinecontaining medication study participation Serum chloride outside normal reference range Neurological impairment due condition ALS , include history transient ischemic attack within past year Presence screening medically significant cardiac , pulmonary , GI , musculoskeletal , psychiatric illness might interfere patient 's ability comply study procedure might confound interpretation clinical safety efficacy data , include , limited : 1 . Poorly control hypertension 2 . NYHA Class II great congestive heart failure 3 . Chronic obstructive pulmonary disease asthma require daily use bronchodilator medication 4 . GI disorder might impair absorption study drug 5 . History significant liver disease define bilirubin &gt; 2 time upper limit normal ( ULN ) ALT AST &gt; 3 time ULN repeat test 6 . Poorly control diabetes mellitus 7 . History vertigo within three month study entry 8 . History syncope without explainable treat cause 9 . History untreated intracranial aneurysm poorly control seizure disorder 10 . Amputation limb 11 . Cognitive impairment , related ALS otherwise , sufficient impair patient 's ability give inform consent understand and/or comply study procedures 12 . Cancer metastatic potential ( basal cell carcinoma , carcinoma situ cervix , squamous cell carcinoma skin excise clean margin ) diagnose treat within last two year 13 . Any condition , impairment social circumstance , opinion Investigator , would render patient suitable participate study 14 . Patient judge actively suicidal suicide risk Investigator Has take investigational study drug within 30 day five halflives prior agent , whichever great , prior dose Prior participation form stem cell therapy treatment ALS Previously receive tirasemtiv previous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>fast skeletal troponin activator</keyword>
	<keyword>tirasemtiv</keyword>
	<keyword>CK-2017357</keyword>
	<keyword>double-blind</keyword>
	<keyword>randomize</keyword>
	<keyword>placebo-controlled</keyword>
</DOC>